Press releases

2018-04-24 – Press release

Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement

Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies)
Initial focus on next generation vector-based therapeutics
Boehringer Ingelheim is granted option to in-license several pre-clinical development candidates produced under the collaboration

2018-01-25 – Press release

Topas Therapeutics serves as exclusive translational partner for Collaborative Research Center focused on liver inflammation at University Medical Center Hamburg-Eppendorf

Funding for Collaborative Research Center (CRC) 841 at University Medical Center Hamburg-Eppendorf (UKE) extended for 4 years in the amount of nearly EUR 15 million.
Topas Therapeutics will act as exclusive partner for indication expansions and translation of research results into clinical development.

2017-11-02 – Press release

Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund

Corporate venture fund invests EUR 4 million (USD 5 million) into Topas
Financing to accelerate clinical trials in autoimmune diseases
Detlev Mennerich, Ph.D., Investment Manager of BIVF, to join Topas’ Board ofDirectors

2017-10-26 – Press release

Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer

Highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Bayer and Schering
To lead Topas’ clinical development and regulatory affairs

2017-08-22 – Press release

Topas Therapeutics signs multi-year research and option agreement with Lilly focused on immune tolerance